TABLE 4.
MRL strain | MIC (μg/ml) |
FICI | Interpretationa | |||
---|---|---|---|---|---|---|
Drug tested alone |
Drug in combination |
|||||
SCY-078 | AMB | SCY-078 | AMB | |||
20438 | 4 | 4 | 0.016 | 0.5 | 0.13 | S |
4 | 4 | 0.016 | 0.5 | 0.13 | S | |
28378 | 4 | 2 | 0.016 | 0.5 | 0.25 | S |
4 | 2 | 0.016 | 0.5 | 0.25 | S | |
28382 | 4 | 4 | 0.016 | 1 | 0.25 | S |
8 | 4 | 0.063 | 0.5 | 0.13 | S | |
28401 | 4 | 4 | 0.016 | 1 | 0.25 | S |
8 | 4 | 0.031 | 0.5 | 0.13 | S | |
28383b | 4 | 4 | 0.016 | 4 | 1 | NI |
4 | 2 | 0.125 | 2 | 1.03 | NI | |
28500b | 4 | 4 | 0.016 | 1 | 0.25 | S |
4 | 4 | 0.125 | 1 | 0.28 | S |
S, synergistic interaction (FICI ≤ 0.5); NI, no interaction (0.5 < FICI ≤ 4.0).
Azole-resistant strains.